Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry
Abstract There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national r...
Enregistré dans:
Auteurs principaux: | Steven M. Bradley, Sophia Emmons-Bell, R. Kannan Mutharasan, Fatima Rodriguez, Divya Gupta, Gregory Roth, Ty J. Gluckman, Rashmee U. Shah, Tracy Y. Wang, Rohan Khera, Pamela N. Peterson, Sandeep Das |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/86e2f28a42fa4d5789e3d0e70e0830b6 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Irreducible Cognitive Phenomenology and the Aha! Experience
par: John Joseph Dorsch
Publié: (2017) -
Protocol for DRAUP: a deimplementation programme to decrease routine chest radiographs after central venous catheter insertion
par: Christopher Carpenter, et autres
Publié: (2021) -
Impact of CVD knowledge, risk perception, and barriers to healthcare on routine CVD management in Coimbatore, India
par: I. Balachandran, et autres
Publié: (2015) -
Living with cardiovascular disease (CVD): Exploring the biggest challenges for people affected by CVD in the UK, and their use (or not) of online resources
par: Sarah-Ann Burger, et autres
Publié: (2020) -
INCREASING STATIN USE IN DIABETICS FOR CVD PREVENTION
par: Karsh Gaurav, et autres
Publié: (2021)